<?xml version="1.0" encoding="UTF-8"?>
<p id="p0045">It is well known that high drug deposition in the pharynx and larynx is undesirable and is challenging to be avoided in conventional DPI formulations
 <xref rid="bib24" ref-type="bibr">
  <sup>24</sup>
 </xref>. For instance, in the case of inhaled lactose-based DPIs, a considerable part of the carrier lactose deposits in the larynx without being delivered to the lungs
 <xref rid="bib25" ref-type="bibr">
  <sup>25</sup>
 </xref>. In most cases, the incorporation of lactose in the carrier is not for improved laryngeal adhesion of drugs but to enhance the powder flowability
 <xref rid="bib26" ref-type="bibr">
  <sup>26</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib27" ref-type="bibr">
  <sup>27</sup>
 </xref>. Lactose deposits in the larynx mainly due to its large particle size without drug loading capability
 <xref rid="bib28" ref-type="bibr">
  <sup>28</sup>
 </xref>. Therefore, it is of great importance to develop the new carrier to achieve the targeted drug deposition and localization of the larynx.
</p>
